[EN] SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1<br/>[FR] MODULATEURS À PETITES MOLÉCULES DU DOMAINE BTB DE KEAP1
申请人:MEDIMMUNE LTD
公开号:WO2019122265A1
公开(公告)日:2019-06-27
The present application relates to compounds of formula (I') or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).
本申请涉及式(I')或式(I)的化合物,例如式(Ia),以及它们的药物组合物/制剂。本申请还涉及治疗或预防神经退行性疾病的方法,如阿尔茨海默病(AD)、帕金森病(PD)、亨廷顿病(HD)和其他CAG三联重复(或多谷氨酰胺)疾病、肌萎缩侧索硬化(ALS;路易·盖里格病)、弥漫性小体病、舞蹈-棘红细胞病、原发性侧索硬化、多发性硬化(MS)、额颞叶痴呆、弗里德雷希共济失调、急性头部损伤和癫痫(抑制小胶质细胞活化)。